Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep 22;32(13):1273-1285.
doi: 10.1093/eurjpc/zwae356.

Defective biological activities of high-density lipoprotein identify patients at highest risk of recurrent cardiovascular event

Johanne Silvain  1   2 , Clément Materne  2 , Michel Zeitouni  1   2 , Niki Procopi  1   2 , Paul Guedeney  1   2 , Delphine Brugier  1   2 , Sophie Galier  2 , Marie Lhomme  3 , Maharajah Ponnaiah  3 , Isabelle Guillas  2 , Pukar Kc  2 , Veronica D Dahik  2 , Eric Frisdal  2 , Eric Vicaut  1   4   5 , Philippe Lesnik  2 , Ghilas Rahoual  1 , Wilfried Le Goff  2 , Gilles Montalescot  1   2 , Mathieu Kerneis  1   2 , Maryse Guerin  2
Affiliations

Defective biological activities of high-density lipoprotein identify patients at highest risk of recurrent cardiovascular event

Johanne Silvain et al. Eur J Prev Cardiol. .

Abstract

Aims: Low cholesterol efflux capacity (CEC) and elevated levels of interleukin-1ß (IL-1ß) are both associated with residual cardiovascular risk in patients with acute myocardial infarction (MI) and may be used as new biomarkers to identify patients at higher cardiovascular risk.

Methods and results: We evaluated potential synergetic effect of CEC and IL-1ß on recurrent major adverse cardiovascular events (MACE) at 1 year in 2012 patients with acute ST-segment elevation MI who underwent primary percutaneous coronary intervention. In addition, we evaluated the contribution to residual risk of HDL biological functions from 20 patients of the two extreme subgroups, focusing on CEC and anti-inflammatory properties. Patients with MACE during the first year after the MI had significantly lower serum CEC as compared with those without recurrent events and higher level of IL-1ß, and both associations were confirmed after multivariate analysis. We found an inverse relationship between CEC and circulating levels of the inflammatory marker IL-1ß, defining a very high risk (low CEC/high IL-1ß) and a low risk (high CEC/low IL-1ß) group of patients. Patients combining low CEC/high IL-1ß exhibited the highest risk of recurrent MACE at 1 year showing an additive prognostic value of these biomarkers, regardless of all the other clinical or biological factors. In this very high-risk subgroup, patients exhibited reduced HDL efflux capacity and defective ABCA1 and SR-BI with enhanced pro-inflammatory activity as a potential explanation for our clinical findings.

Conclusion: Impaired CEC and elevated IL-1β synergistically increase the residual cardiovascular risk in MI patients, which could be explained by reduced HDL efflux capacity and enhanced HDL pro-inflammatory activity.

Keywords: Cholesterol efflux; HDL; IL-1β; Inflammation; MACE; Myocardial infarction.

Plain language summary

This study examined the potential synergetic effect of cholesterol efflux capacity and IL-1ß on recurrent major adverse cardiovascular events at 1 year in patients with acute ST-segment elevation myocardial infarction.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: J.S. reports during the past 2 years the consulting fees or lecture fees from AstraZeneca, Bayer HealthCare SAS, Sanofi-Aventis France, and Zoll and was a stockholder of 4P Pharma. C.M. has no conflict of interest to declare. M.Z. reports during the past 2 years the consulting fees or lecture fees from AztraZeneca, Bayer, and Novordisk. D.B. has no conflict of interest to declare. S.G. has no conflict of interest to declare. I.G. has no conflict of interest to declare. P.K. has no conflict of interest to declare. V.D.D. has no conflict of interest to declare. M.L. has no conflict of interest to declare. E.F. has no conflict of interest to declare. E.V. reports consulting or speaker fees from Abbott and Bristol Myers Squibb. P.L. has no conflict of interest to declare. W.L.G. has no conflict of interest to declare. G.M. reports consulting or speaker fees from Abbott, Amgen, AstraZeneca, Axis, Bayer, BMS, Boehringer Ingelheim, Boston Scientific, Cell Prothera, CSL Behring, Idorsia, Leo-Pharma, Lilly, Medtronic, Novartis, Pfizer, Quantum Genomics, Sanofi, and Terumo. M.K. reports during the past 2 years the consulting fees or lecture fees from Bayer HealthCare SAS, Sanofi-Aventis France, Eligo, and Kiniksa. M.G. has no conflict of interest to declare.

Comment in